- Vetter, a global CDMO, plans to expand its Development Services site from Skokie, IL, to Des Plaines, and invest in its commercial business in Southwest Germany.
- The company aims to double the capacity of its U.S. services and plans to start pharmaceutical production at a new site in Saarlouis, Saarland by 2030, creating up to 2,000 new local jobs.
Vetter, a global Contract Development and Manufacturing Organization (CDMO), has announced plans to expand its Development Services site from Skokie, IL, to Des Plaines. This move is part of a strategic plan to further invest in its U.S. operations. In addition, the company is planning a major investment in its commercial business in Southwest Germany. These investments are designed to complement its ongoing capacity expansions in Ravensburg and Langenargen.
Udo J. Vetter, Chairman of the Advisory Board and member of the owner family, stated, “As an independent and family-owned company, we prioritize thoughtful and strategic planning to support our long-term business growth.” He added that these investments reaffirm the company’s commitment on both continents and ensure that Vetter Pharma will continue to be part of a growing market in the future.
The decision to expand was made in response to the growing customer needs at the current Skokie site, as well as at the company’s clinical manufacturing site in Rankweil, Austria. The development plan involves a construction project at the Des Plaines site and the relocation and expansion of Vetter Development Services U.S. from the Illinois Science and Technology Park over the next few years. This move will effectively double the capacity of Vetter Development Services in the U.S. and provide ample space for future expansion opportunities.
In addition to the U.S. expansion, Vetter plans an additional investment of several hundred million Euro for a commercial production site in Saarlouis, Saarland. This aims to support access to an existing network of suppliers and the use of the company’s internal infrastructure. Pharmaceutical production at the site is expected to start by 2030 and Vetter is planning to create up to 2,000 new local jobs in the years to come.
Thomas Otto, Managing Director, said, “After careful consideration, Germany, and Saarland in particular, prove to be the location with the best-fitting conditions for expanding our commercial operations. We are taking responsibility for patients and customers worldwide who rely on our high level of quality.” This expansion will allow Vetter to further expand its range of services, meeting the needs of patients and customers worldwide.
Overview of outsourcing trends 
